IBS and Chronic Constipation Journal Articles

• Factors Predicting Response to Low FODMAP Diet in IBS Are differences in fecal microbiota and/or fecal and urine metabolites associated with response to the low FODMAP diet in patients with irritable bowel syndrome?
  Alimentary Pharmacology & Therapeutics, August 24, 2023
• Post-COVID-19 Functional Dyspepsia and Irritable Bowel Syndrome Are COVID-19 survivors at higher risk for development of IBS or functional dyspepsia compared to controls?
  Alimentary Pharmacology & Therapeutics, July 20, 2023
• Type 1 Diabetes and Microscopic Colitis Both microscopic colitis and type 1 diabetes are autoimmune diseases. Is there an association between the two?
  Alimentary Pharmacology & Therapeutics, July 06, 2023
• Functional Dyspepsia and Pregnancy--Effects and Management This systematic review examined the interactions between functional dyspepsia and pregnancy. How should FD be managed in the peripartum and post-partum periods?
  Alimentary Pharmacology & Therapeutics, July 04, 2023
• Ondansetron for Irritable Bowel Syndrome With Diarrhea This placebo-controlled RCT demonstrated the efficacy of titrated ondansetron for managing key symptoms of IBS-D.
  Alimentary Pharmacology & Therapeutics, June 15, 2023
• Current Evidence for Dietary Therapies in IBS Dietary changes could help improve the symptoms of IBS. This review looks at the efficacy of three different diet plans.
  Current Opinion in Gastroenterology, May 29, 2023
• Delayed GE in Patients With Gastroparesis-like Symptoms How might symptom patterns differentiate gastroparesis from functional dyspepsia, and what role does delayed gastric emptying play in diagnosis?
  Alimentary Pharmacology & Therapeutics, April 11, 2023
• Gluten-free Diet for Primary Sclerosing Cholangitis Might patients with primary sclerosing cholangitis benefit from a gluten-free/amylase trypsin inhibitor-free diet?
  Alimentary Pharmacology & Therapeutics, January 31, 2023
• Effects of MD-7246 on Irritable Bowel Syndrome With Diarrhea This study evaluated the efficacy, safety and dose-response of MD-7246, a delayed-release formulation of linaclotide, in patients with IBS-D.
  Alimentary Pharmacology & Therapeutics, January 24, 2023
• Efficacy, Safety of the Live Biotherapeutic MRx1234 in IBS MRx1234, a live biotherapeutic, has the potential to become a novel, safe treatment option for patients with irritable bowel syndrome, according to this RCT.
  Alimentary Pharmacology & Therapeutics, January 05, 2023
• Advances in the Gut Microbiome and Mood Disorders This review summarizes recent advances in our understanding of the role of the gut microbiome in mood disorders, including the use of psychobiotics for the treatment and prevention of these disorders.
  Current Opinion in Psychiatry, December 21, 2022
• Gluten-free Diet and the Gut Microenvironment in IBS Might a gluten-free diet reduce GI symptoms in patients with irritable bowel syndrome? This study investigated how a gluten-free diet alters the gut microenvironment in IBS patients.
  Alimentary Pharmacology & Therapeutics, November 18, 2022
• Natural History and Impact of IBS-type Symptoms in IBD This study aimed to characterize the course of IBS-type symptoms over the long-term in patients with IBD, as well as their impact on prognosis.
  Alimentary Pharmacology & Therapeutics, October 26, 2022
• Mesalazine Treatment in Irritable Bowel Syndrome Is the anti-inflammatory drug mesalazine effective in reducing symptoms of irritable bowel syndrome?
  Alimentary Pharmacology & Therapeutics, September 28, 2022
• Chronic Pain in the 11th Revision of the ICD This article presents answers to frequently asked questions regarding the new, more comprehensive ICD-11 chronic pain classification, and its application to common pain syndromes.
  Pain, September 27, 2022
• Polypharmacy and HRQoL Among Patients With Chronic Disease Does polypharmacy negatively impact the psychological domain of HRQoL as well as the physical domain among patients with chronic diseases?
  Preventing Chronic Disease, September 22, 2022
• Nonpsychiatric Indications for Antidepressants, Antipsychotics Review off-label, nonpsychiatric indications for antidepressants and antipsychotics by way of this case presentation of a woman with abdominal pain and hiccups.
  Current Psychiatry, September 21, 2022
• Efficacy of Peppermint Oil in Irritable Bowel Syndrome This meta-analysis examined the latest evidence on the efficacy of peppermint oil in relieving symptoms of irritable bowel syndrome. Is the quality of evidence sufficient to recommend it?
  Alimentary Pharmacology & Therapeutics, September 21, 2022
• A New Way of Thinking About Pains In this commentary, the author proposes abandoning the traditional temporal construct of acute pain vs. chronic pain in favor of a more patient-centric approach.
  Pain, September 13, 2022
• Associations of Disease Severity Index With IBD Characteristics Is the disease severity index, which aims to gauge the overall severity of IBD, useful in predicting long-term IBD-related outcomes?
  Alimentary Pharmacology & Therapeutics, September 05, 2022